27 June 2019 
EMA/368428/2019  
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
Keytruda/ pembrolizumab 
Pharmaceutical form(s): 
See Annex A of the CHMP Opinion 
Strength(s): 
See Annex A 
Route(s) of administration: 
See Annex A 
Packaging and package size(s):  See Annex A 
Number(s)in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  Merck Sharp & Dohme B.V. 
Waarderweg 39 
2031 BN Haarlem 
NETHERLANDS 
Procedure  
Procedure number: 
EMEA/H/C/003820/II/0071 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
-the development of this product has complied with all measures in the agreed paediatric investigation 
plan P/0043/2018. All studies in the agreed paediatric investigation plan P/0043/2018 were conducted 
after the entry into force of that Regulation, 
-the Summary of Product Characteristics reflects the results of studies conducted in compliance with this 
agreed paediatric investigation plan. 
In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance 
with the agreed completed paediatric investigation plan P/0043/2018 is included in the technical dossier. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
 
  
 
 
 
 
 
 
 
  
